Back to search results

Study of Oral THC and CBD in Men and Women

This study is looking at how oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) affect the body. Researchers want to understand how these substances are processed (pharmacokinetics) and what effects they have (pharmacodynamics). They are also testing devices that can detect recent THC use in saliva. You might be able to join if you are a man or non-pregnant woman between 21 and 55 years old, use cannabis weekly or monthly (but not seeking treatment for it), and have a BMI between 18.5 and 34. The study will measure your subjective drug effects, levels of THC and CBD in your blood, and your performance on a behavioral task. The current status of this study is unclear.

Study design
This is a double-blind, placebo-controlled study, meaning neither you nor the researchers will know if you are receiving THC, CBD, a combination, or a placebo. It involves about 22 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your subjective drug effects, blood concentrations, and behavioral task performance will be measured at 6 hours after taking the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05067387

Evaluation of Oral THC and CBD in Men and Women

Not Yet Recruiting
PHASE1Ages 21–55InterventionalBasic science
University of California, Los Angeles
~22 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:PlaceboTHCCBDTHC + CBD

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ratings of subjective drug effects
Measured over 6 hours
+3 more outcomes measured

Conditions

Drug Abuse
Intoxication by Drug
Impairment

Explore related trials

Cannabis misuse

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ziva Cooper · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Ziva Cooper, PhD
[email protected]
310-206-9942
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or non-pregnant and non-lactating females aged 21-55 years
Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,
Not currently seeking treatment for their cannabis use
Have a Body Mass Index from 18.5 - 34kg/m2.
Able to perform all study procedures
Must be using a contraceptive (hormonal or barrier methods)

Exclusion

Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine
Any other Axis I disorder
Report using other illicit drugs in the prior 4 weeks, other than cannabis.
Current use of any medications that may affect study outcomes
If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
History of an allergic reaction or adverse reaction to cannabis is exclusionary.
History of respiratory illness or current respiratory illness
Currently enrolled in another research protocol
Not using a contraceptive method (hormonal or barrier methods)
The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.

What this trial measures

  • Ratings of subjective drug effects6 hours

    Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).

  • Concentration of THC, CBD and metabolites in whole blood6 hours

    Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH as measured in ng/ml

  • Behavioral task performance as assessed by the DRUID App Score6 hours

    Composite score on the DRUID App, a measure of behavioral task performance (range 0-100) where lower scores indicate better performance

  • Concentration of THC in oral fluid6 hours

    Liquid chromatography-tandem mass spectrometry